Format

Send to

Choose Destination
Oncotarget. 2017 Apr 25;8(17):28672-28682. doi: 10.18632/oncotarget.15639.

Adipophilin as prognostic biomarker in clear cell renal cell carcinoma.

Author information

1
Institute for Pathology, University Hospital Bonn, Bonn, Germany.
2
Berlin Institute of Urologic Research, Berlin, Germany.

Abstract

OBJECTIVE:

To study the expression of adipophilin (PLIN2), a lipid storage-associated cell protein, in different subtypes of renal cell cancer and to elucidate its prognostic value.

MATERIALS AND METHODS:

Two-hundred-seventy-five patients with renal cell carcinoma (RCC) were included in this study. Immunohistochemistry with a polyclonal antibody to adipophilin was used on the tissue microarray (formalin-fixed, paraffin-embedded tissue) for detection of adipophilin. Median follow-up time was 91 (range 1-159) months in the whole cohort and 100 (1-159) months for patients with clear-cell RCC. Additional validation for adipophilin was performed using publicly available gene expression data for clear cell RCC from The Cancer Genome Atlas (TCGA).

RESULTS:

Adipophilin expression was detected in 14.3% of papillary RCC, in 0% of chromophobe RCC and in 58.7% of clear-cell RCC in the cytoplasm or at the membrane. Only membrane expression was correlated with other clinical parameters (pT-stage, pN-stage, R-status, sex) and showed a prognostic significance in univariate analysis with regard to overall survival of patients with clear cell subtype (HR 2.90, 95% CI 1.55-5.42, p=0.001), which failed significance on multivariate analysis. mRNA expression of PLIN2 on TCGA data using best selected cut-off was prognostically significant in both univariate (HR 1.76, 95% CI 1.28-2.42, p = 0.0005) and multivariate analyses (HR 1.46, 95% CI 1.05-2.04, p = 0.0257).

CONCLUSIONS:

Adipophilin is a novel and still understudied prognostic biomarker in clear cell renal cell carcinoma which deserves further study.

KEYWORDS:

PLIN2; adipophilin; clear cell; perilipin 2; renal cell carcinoma

PMID:
28404922
PMCID:
PMC5438682
DOI:
10.18632/oncotarget.15639
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center